Log in

Xencor Stock Price, Forecast & Analysis (NASDAQ:XNCR)

$35.98
+0.02 (+0.06 %)
(As of 11/16/2019 08:00 AM ET)
Today's Range
$35.62
Now: $35.98
$36.35
50-Day Range
$32.20
MA: $34.86
$37.05
52-Week Range
$27.75
Now: $35.98
$46.33
Volume273,900 shs
Average Volume256,689 shs
Market Capitalization$2.04 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.34
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:XNCR
CUSIPN/A
Phone626-305-5900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$40.60 million
Book Value$10.76 per share

Profitability

Net Income$-70,410,000.00

Miscellaneous

Employees156
Market Cap$2.04 billion
Next Earnings Date2/24/2020 (Estimated)
OptionableOptionable

Receive XNCR News and Ratings via Email

Sign-up to receive the latest news and ratings for XNCR and its competitors with MarketBeat's FREE daily newsletter.


Xencor (NASDAQ:XNCR) Frequently Asked Questions

What is Xencor's stock symbol?

Xencor trades on the NASDAQ under the ticker symbol "XNCR."

How were Xencor's earnings last quarter?

Xencor Inc (NASDAQ:XNCR) announced its earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.58) by $0.40. The biopharmaceutical company earned $21.76 million during the quarter, compared to the consensus estimate of $4.62 million. Xencor had a return on equity of 5.84% and a net margin of 21.60%. View Xencor's Earnings History.

When is Xencor's next earnings date?

Xencor is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Xencor.

What price target have analysts set for XNCR?

10 equities research analysts have issued 12-month price targets for Xencor's shares. Their forecasts range from $21.00 to $67.00. On average, they anticipate Xencor's share price to reach $44.49 in the next twelve months. This suggests a possible upside of 23.6% from the stock's current price. View Analyst Price Targets for Xencor.

What is the consensus analysts' recommendation for Xencor?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last year. There are currently 1 sell rating, 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Xencor.

What are Wall Street analysts saying about Xencor stock?

Here are some recent quotes from research analysts about Xencor stock:
  • 1. According to Zacks Investment Research, "Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California. " (11/16/2019)
  • 2. Nomura analysts commented, "‘18087 (SSTR2xCD3) 2H19 to 1H20, 0 Est ASCO as Expected. SSTR2 is a validated target in NET and GIST, but these are solid tumors and suffer from tumor microenvironment effects and potential on-target toxicities. ‘18087 (SSTR2xCD3) is now the only bispecific in XNCR’s platform that we currently value. NVS to Our View. Recall, the clinical hold lifted in April; dosing to resume in coming weeks, but “tunable potency” still in question. Last update on clinicaltrials.gov was May 2 and included a Aug 2019 study completion date – we anticipate with appropriate study completion, NVS will return rights. More p 3. Checks – XNCRs’s Bispec C max -Dependent with Redesign." (8/8/2019)
  • 3. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and 12-month price target of $40. Xencor reported 1Q 2019 earnings and offered a Business Update. No Ultromaris royalties were booked because they are booked ~1-2 quarters in arrears vs. Alexion. The company did have $112M in revenue from February’s Genentech deal, resulting in positive EPS for the quarter. Ultromaris and MOR208 revenues remain fast-approaching, near-term revenue opportunities. Alexion (ALXN: NC) reported $25M in Ultromaris sales in 1Q 2019. Xencor receives a low-single-digit royalty on these revenues; we model a 2% royalty." (5/12/2019)

Has Xencor been receiving favorable news coverage?

Headlines about XNCR stock have trended very negative recently, according to InfoTrie Sentiment. The research firm ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Xencor earned a coverage optimism score of -3.0 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an impact on the company's share price in the immediate future. View News Stories for Xencor.

Who are some of Xencor's key competitors?

What other stocks do shareholders of Xencor own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xencor investors own include Intelsat (I), Cypress Semiconductor (CY), Bank of America (BAC), Fossil Group (FOSL), Apollo Global Management (APO), Associated British Foods (ABF), Chaarat Gold (CGH), Abercrombie & Fitch (ANF), Exelixis (EXEL) and Intel (INTC).

Who are Xencor's key executives?

Xencor's management team includes the folowing people:
  • Dr. Bassil I. Dahiyat Ph.D., Co-Founder, CEO, Pres & Director (Age 49)
  • Mr. John J. Kuch, Sr. VP of Fin., CFO & Sec. (Age 60)
  • Dr. John R. Desjarlais, Sr. VP of Research & Chief Scientific Officer (Age 55)
  • Dr. Paul A. Foster, Sr. VP & Chief Medical Officer (Age 65)
  • Mr. Charles Liles, Associate Director and Head of Corp. Communications & Investor Relations

Who are Xencor's major shareholders?

Xencor's stock is owned by a number of of institutional and retail investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.53%), Rhumbline Advisers (0.29%), California Public Employees Retirement System (0.17%), First Trust Advisors LP (0.13%), New York State Teachers Retirement System (0.10%) and State of New Jersey Common Pension Fund D (0.09%). Company insiders that own Xencor stock include Bassil I Dahiyat, Edgardo Baracchini Jr, Edgardo Baracchini, Jr, John J Kuch, John R Desjarlais, John S Stafford III and Paul A Foster. View Institutional Ownership Trends for Xencor.

Which institutional investors are selling Xencor stock?

XNCR stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Mackay Shields LLC, CIBC Private Wealth Group LLC and Chicago Equity Partners LLC. Company insiders that have sold Xencor company stock in the last year include John J Kuch and John R Desjarlais. View Insider Buying and Selling for Xencor.

Which institutional investors are buying Xencor stock?

XNCR stock was purchased by a variety of institutional investors in the last quarter, including Rhumbline Advisers, First Trust Advisors LP, New York State Teachers Retirement System, California Public Employees Retirement System, State of New Jersey Common Pension Fund D, Comerica Bank, State of Alaska Department of Revenue and State of Tennessee Treasury Department. View Insider Buying and Selling for Xencor.

How do I buy shares of Xencor?

Shares of XNCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Xencor's stock price today?

One share of XNCR stock can currently be purchased for approximately $35.98.

How big of a company is Xencor?

Xencor has a market capitalization of $2.04 billion and generates $40.60 million in revenue each year. The biopharmaceutical company earns $-70,410,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis. Xencor employs 156 workers across the globe.View Additional Information About Xencor.

What is Xencor's official website?

The official website for Xencor is http://www.xencor.com/.

How can I contact Xencor?

Xencor's mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The biopharmaceutical company can be reached via phone at 626-305-5900 or via email at [email protected]


MarketBeat Community Rating for Xencor (NASDAQ XNCR)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  408 (Vote Outperform)
Underperform Votes:  254 (Vote Underperform)
Total Votes:  662
MarketBeat's community ratings are surveys of what our community members think about Xencor and other stocks. Vote "Outperform" if you believe XNCR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XNCR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/17/2019 by MarketBeat.com Staff

Featured Article: Dividend Aristocrat Index

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel